MillerDRudickRAHutchinsonM. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology2010; 74Suppl 3: S24–35.
2.
HobartJRiaziALampingDL. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? A comparison with some other self report scales. J.Neurol Neurosurg Psychiatry2005: 1539–1543.
3.
SharpeLButowPSmithC. Changes in quality of life in patients with advanced cancer: evidence of response shift and response restriction. J Psychos Res2005; 58: 497–504.
4.
AhmedSMayoNEWood-DauphineeS. Using the patient generated index to evaluate response shift post-stroke. Qual Life Res2005; 14: 2247–2257.
5.
KernRBrownA. Disease adaptation may have decreased quality of life responsiveness in patients with chronic progressive neurological disorders. J Clin Epidemiol2004; 57: 1033–1039.
6.
HobartJLampingDFitzpatrickR. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient based outcome measure. Brain2001; 124: 962–973.
7.
CostelloeLO’RourkeKKearneyH. The atient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry2007; 78: 841–844.
8.
HutchinsonM. Relapses do not matter in relation to long-term disability: Commentary. Mult Scler J2011; 17: 1417.
